Angelman syndrome

- News
Pandemic poses opportunity to online learning platform OpenLearning
Public
- News
Novatti partners with Ripple for global blockchain payments network
Public
- Opinion
Is ASX: OOO the riskiest or smartest oil investment?
Public
- Opinion
What the SportsBet-BetEasy merger means for TabCorp and punters
Public

Crowd Media adds voice cloning for immersive celebrity experiences in AI deal
- Review
- January 27, 2021
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti to drive Malaysia into the digital payments era with ATX acquisition
- Review
- October 20, 2021
Apiam expands equine vet footprint in Queensland in time for breeding season
- Review
- June 30, 2021
Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials
- Review
- March 24, 2020

Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
- News
Neuren secures European patent for drug aimed to treat incurable brain disorders
- News
Noxopharm achieves significant pain relief for late-stage prostate cancer patients
- News

- News
Neuren Pharmaceuticals gains approval for trial in yet another neurodevelopmental disorder
The complexity of the human body never ceases to amaze me. So many systems need to work together to carry out seemingly simple tasks like walking, breathing and digesting. This complexity means that from time to time the convoluted web of neurons, strands of DNA and woven matrices of bone can be subject to defects.
Read More
Public
- News
Neuren secures European patent for drug aimed to treat incurable brain disorders
Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read More
Public